CymaBay Therapeutics Inc. (CBAY)
NASDAQ: CBAY
· Real-Time Price · USD
32.48
0.01 (0.03%)
At close: Mar 21, 2024, 9:00 PM
CymaBay Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 31.07M | 31.02M | 31.02M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 681K | 810K | 777K | 740K | 541K | 356K | 174K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 30.39M | 30.21M | 30.24M | -740K | -541K | -356K | -174K | n/a | n/a | n/a | n/a | n/a |
Operating Income | -101.68M | -82.66M | -71.81M | -95.48M | -93.11M | -94.14M | -94.97M | -94.47M | -87.58M | -78.95M | -68.41M | -56.29M |
Interest Income | 13.49M | 8.73M | 6.24M | 3.93M | 2.02M | 1.12M | 475K | 198K | 167K | 262K | 462K | 844K |
Pretax Income | -105.37M | -90.1M | -80.72M | -107.01M | -106M | -105.91M | -104.09M | -100.22M | -90M | -79.21M | -67.94M | -55.45M |
Net Income | -111.68M | -106.16M | -99.92M | -129.53M | -125.48M | -115.64M | -110.68M | -103.48M | -90M | -79.21M | -67.94M | -55.45M |
Selling & General & Admin | 51.95M | 39.39M | 33.05M | 27.35M | 25.12M | 23.97M | 23.25M | 23.89M | 23.04M | 22.12M | 21.44M | 18.31M |
Research & Development | 80.74M | 74.28M | 69.78M | 68.13M | 68M | 70.17M | 71.72M | 70.58M | 64.54M | 56.83M | 47.56M | 38.76M |
Other Expenses | -5K | -2K | n/a | 2K | 2K | 2K | 2K | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 132.7M | 113.67M | 102.83M | 95.48M | 93.11M | 94.14M | 94.97M | 94.47M | 87.58M | 78.95M | 69M | 57.07M |
Interest Expense | 18.95M | 17.94M | 16.91M | 15.95M | 14.91M | 12.89M | 9.6M | 5.95M | 2.58M | 522K | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 132.75M | 113.67M | 102.83M | 95.48M | 93.11M | 94.14M | 94.97M | 94.47M | 87.58M | 78.95M | 69M | 57.07M |
Income Tax Expense | 6.09M | 15.84M | 19.2M | 22.52M | 19.48M | 9.73M | 6.62M | 3.3M | 29K | -94K | -123K | -123K |
Shares Outstanding (Basic) | 113.32M | 105.72M | 102.15M | 97.97M | 87.81M | 84.68M | 84.68M | 86.78M | 69.02M | 69.02M | 68.99M | 68.95M |
Shares Outstanding (Diluted) | 113.32M | 105.72M | 102.15M | 97.97M | 87.81M | 87.8M | 87.8M | 87.8M | 69.02M | 69.02M | 68.99M | 68.95M |
EPS (Basic) | -1.06 | -1.1 | -1.11 | -1.46 | -1.46 | -1.43 | -1.43 | -1.41 | -1.3 | -1.15 | -0.99 | -0.81 |
EPS (Diluted) | -1.06 | -1.1 | -1.09 | -1.43 | -1.42 | -1.39 | -1.41 | -1.4 | -1.3 | -1.15 | -0.99 | -0.81 |
EBITDA | -94.8M | -75.65M | -63.95M | -91.24M | -91.3M | -92.32M | -93.8M | -93.62M | -86.84M | -78.24M | -67.52M | -55.42M |
EBIT | -96.11M | -81.85M | -63.81M | -91.06M | -91.09M | -93.02M | -94.49M | -94.31M | -87.53M | -78.92M | -56.76M | -44.64M |
Depreciation & Amortization | 3.18M | 4.04M | 4.69M | 4.97M | 2.54M | 1.8M | 1.11M | 791K | 688K | 679K | 662K | 643K |